Home › Cancro al seno › New Jersey › Clifton
Studi clinici su Cancro al seno a Clifton, NJ
12 studi su Cancro al seno cercano partecipanti presso sedi a Clifton e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
In reclutamentoFase 3
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack · a 7 mi di distanza
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
In reclutamentoFase 3
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001), Hackensack · a 7 mi di distanza
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
In reclutamentoFase 3
- Hackensack Univ Medical Center (HUMC) ( Site 0007), Hackensack · a 7 mi di distanza
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack · a 7 mi di distanza
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
In reclutamentoFase 3
- John Theurer Ctr-Hackensack UMC, Hackensack · a 7 mi di distanza
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
In reclutamentoFase 2
- Hackensack Meridian Health, Hackensack · a 7 mi di distanza
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
In reclutamentoFase 1/2
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack · a 7 mi di distanza
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
In reclutamentoFase 3
- Hackensack University Medical Center, Hackensack · a 7 mi di distanza
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
In reclutamentoFase 1
- John Theurer Cancer Ctr at Hackensack Univ. Med Ctr., Hackensack · a 7 mi di distanza
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
In reclutamentoFase 3
- Hackensack University Medical Center, Hackensack · a 7 mi di distanza
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
In reclutamentoFase 1
- Hackensack University Medical Center, Hackensack · a 7 mi di distanza
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
In reclutamentoStudio osservazionale
- John Theurer Cancer Center, Hackensack · a 7 mi di distanza
Studi su Cancro al seno in altre città
- New York City, NY136 studi
- Houston, TX126 studi
- Boston, MA112 studi
- Nashville, TN81 studi
- Los Angeles, CA73 studi
- Edison, NJ68 studi
- St. Louis, MO64 studi
- Queens, NY64 studi
- Durham, NC64 studi
- Chicago, IL59 studi
- Philadelphia, PA56 studi
- Dallas, TX55 studi
Altri studi a Clifton
- Cancro del polmone non a piccole cellule24 studi
- Cancro (tutti i tipi)15 studi
- Mieloma multiplo14 studi
- Cancro metastatico12 studi
- Leucemia mieloide acuta12 studi
- Cancro alla prostata12 studi
- Cancro ovarico11 studi
- Cancro ai polmoni10 studi
- Cancro colorettale8 studi
- Carcinoma a cellule squamose della testa e del collo8 studi
- Cancro dell'endometrio8 studi
- Insufficienza cardiaca8 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.